Skip to content
Menu

Ultragenyx Pharmaceutical Inc. RARE

Full chart Compare
Set alert

Price alert · RARE

All alert types
15.90 USD -0.18 (-1.12%)

Regular-session close

15.90 0.00 0.00%

After hours · Nov 16, 4:00 PM ET

15.79 Day range 16.39
12.73 52-week range 39.89
YTD
-30.87%
1 year
-51.93%
Market cap
1.62B
Revenue (ttm)
730.00M
Profit margin
-71.78%
EPS (ttm)
-5.17
Shares out
101.92M
Forward P/E
11.10
YTD return
-30.87%
1-year return
-51.93%
50-day average
15.29
200-day average
22.53
Volume
5.25M
Avg volume
4.54M
Open
15.88
Previous close
16.08
Day's range
15.79 – 16.39
52-week range
12.73 – 39.89
Beta
0.36
Analysts
Buy
Price target
25.35 (+59.4%)
Earnings date
Feb 11, 2027

5D -0.23 (-1.43%)

15.501616.50TueWedThuFriMon15.90

Key statistics

Enterprise value
2.56B
Price / sales
2.22
Revenue growth
8.10%
Free cash flow
-179.38M
Total cash
266.00M
Total debt
1.19B
Short % of float
23.95%

Fundamental scorecard

6 of 25 checks passed on RARE’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RARE Revenue — quarterly 173.00M
RARE Net income — quarterly -118.00M
RARE EPS — quarterly -1.16

Earnings

RARE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20262.39———
Nov 3, 2026Sep 30, 2026-1.10-1.16-0.06-5.45%
Aug 4, 2026Jun 30, 2026-1.22-0.90+0.32+26.23%
May 5, 2026Mar 31, 2026-1.49-1.84-0.35-23.67%
Feb 12, 2026Dec 31, 2025-1.20-1.29-0.09-7.50%
Nov 4, 2025Sep 30, 2025-1.23-1.81-0.58-47.15%

Upgrades / downgrades

RARE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026CitigroupmainBuyBuy
Nov 5, 2026BarclaysmainOverweightOverweight
Nov 4, 2026Canaccord GenuitymainBuyBuy
Nov 4, 2026TD CowenmainBuyBuy
Nov 4, 2026Morgan StanleymainEqual-WeightEqual-Weight
Nov 4, 2026Goldman SachsmainNeutralNeutral

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on RARE — it syncs with the Stock Master app.

Insider holders

RARE insider holders
InsiderRelationLatest transactionDateShares held
CROMBEZ ERIC M.D.OfficerSaleMay 4, 2026111,189
HARRIS ERIKOfficerStock Award(Grant)Apr 15, 2026118,410
HORN HOWARDChief Financial OfficerSaleOct 14, 202689,229
HUANG DENNIS KARLChief Technology OfficerStock Award(Grant)Apr 15, 2026147,845
HUIZENGA THEODORE ALANOfficerSaleSep 14, 202667,863
KAKKIS EMIL DChief Executive OfficerStock Award(Grant)Apr 15, 20262,894,720

Institution ownership

RARE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.11.22%11,432,853181.78MSep 29, 2026
Vanguard Portfolio Management LLC8.26%8,419,105133.86MSep 29, 2026
RTW Investments LP7.65%7,796,895123.97MJun 29, 2026
State Street Corporation7.40%7,538,078119.86MSep 29, 2026
AQR Capital Management, LLC6.44%6,560,809104.32MJun 29, 2026
Vanguard Capital Management LLC4.22%4,299,16868.36MSep 29, 2026

Fund ownership

RARE fund ownership
Holder% heldSharesValueReported
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF5.00%5,095,89581.02MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.93%2,986,62147.49MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.45%2,496,49339.69MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.10%2,144,80234.10MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.22%1,238,64019.69MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.11%1,127,71117.93MJun 29, 2026